Nuformix PLC Second tranche of Lanstead subscription shares (0005I)
April 12 2022 - 1:00AM
UK Regulatory
TIDMNFX
RNS Number : 0005I
Nuformix PLC
12 April 2022
12 April 2022
Nuformix plc
("Nuformix" or the "Company")
Second tranche of Lanstead subscription shares
Nuformix plc (LSE: NFX), a pharmaceutical development company
targeting unmet medical needs in fibrosis and oncology via drug
repurposing, is pleased to announce that further to the
notifications of 14 December 2021 and 17 January 2022 relating to
its subscription and associated sharing arrangements with Lanstead
Capital Investors L.P. ("Lanstead"), application has now been made
for trading on the Standard Segment of the Official List and the
Main Market of the London Stock Exchange ("Admission") for the
second tranche of the subscription, comprising 88,000,000 Ordinary
Shares (the "Second Subscription Shares") for gross proceeds of
GBP1,320,000 and the associated 5,700,000 Second Value Payment
Shares.
Full details of the subscription and associated sharing
agreements and the Second Value Payment Shares are set out in the
earlier announcements referenced above.
Admission and dealings in the Second Subscription Shares and the
Second Value Payment Shares, all of which will rank pari passu with
the existing Ordinary Shares, are expected to commence at 8.00 am
on 14 April 2022.
Total Voting Rights
Following Admission of the Second Subscription Shares and the
Second Value Payment Shares the Company's enlarged issued share
capital will comprise 709,309,368 Ordinary Shares with voting
rights. The figure of 709,309,368 Ordinary Shares may therefore be
used by shareholders in the Company as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change in their interest in, the
share capital of the Company under the FCA's Disclosure and
Transparency Rules.
Enquiries:
Nuformix plc
Dr Alastair Riddell, Executive Chairman Via IFC Advisory
Stanford Capital Partners Limited
Tom Price / Patrick Claridge (Corporate
Finance) +44 (0) 20 3650 3650
John Howes (Corporate Broking) +44 (0) 20 3650 3652
IFC Advisory Limited
Tim Metcalfe +44 (0) 20 3934 6630
Zach Cohen nuformix@investor-focus.co.uk
About Nuformix
Nuformix is a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing. The
Company aims to use its expertise in discovering, developing and
patenting novel drug forms, with improved physical properties, to
develop new products in new indications that are, importantly,
differentiated from the original (by way of dosage, delivery route
or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with
potential for significant value and early licensing
opportunities.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEGPUCPCUPPGWG
(END) Dow Jones Newswires
April 12, 2022 02:00 ET (06:00 GMT)
Nuformix (LSE:NFX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Nuformix (LSE:NFX)
Historical Stock Chart
From Jul 2023 to Jul 2024